SITC's Cancer Immunotherapy Guidelines program is a
collectio
n of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent, and balanced. CPGs will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Hepatocellular Carcinoma Immunotherapy Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with hepatocellular carcinoma (HCC). Recently, the checkpoint inhibitor atezolizumab was approved by the U.S. FDA in combination with the anti-VEGF therapy bevacizumab as a first-line treatment for HCC. Additional immunotherapies targeting the PD-(L)-1 axis are approved second-line options. Ongoing trials are evaluating additional immunotherapeutic strategies for this disease state.